28 February 2019 in Annals of Surgical Oncology
1 February 2018 in Surgery
1 September 2015 in Urologic Oncology: Seminars and Original Investigations
10 May 2012 in BJU International
Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? So far, few previous reports have analysed the risk factors for tumour recurrence and stage progression with a special focus on BCG‐relapsing disease, defined as the recurrence after achieving a disease‐free status by initial BCG instillations for 6 months. There are no guidelines outlining a specific treatment strategy for BCG‐relapsing disease, although many BCG failure cases are attributable to BCG‐relapsing disease. In this study, additional BCG instillation was shown to decrease the subsequent tumour recurrence rate against BCG‐relapsing tumours with intermediate pathological risk features; however, a BCG‐relapsing tumour with a pathologically high risk was a significant risk factor for both subsequent tumour recurrence and stage progression. This information might identify a therapeutic strategy for BCG‐relapsing tumours. OBJECTIVE: To investigate the risk of subsequent tumour recurrence and stage progression in bacillus Calmette‐Guérin (BCG)‐relapsing non‐muscle‐invasive bladder cancer, defined as recurrence after achieving a disease‐free status for 6 months. PATIENTS AND METHODS: A total of 183 patients with BCG‐relapsing tumours were treated with conservative therapy between 1985 and 2008 at our three institutions. We analysed the association between their clinicopathological parameters and subsequent tumour recurrence or stage progression. RESULTS: Additional induction courses of BCG or anticancer drug (mitomycin C or epirubicin) instillations were performed in 119 patients and 24 patients, respectively. The remaining 40 patients did not undergo any adjuvant therapy. Multivariate analysis showed that a relapsing tumour with a pathologically high risk (defined as tumours with G3 and/or pT1 and/or concomitant carcinoma in situ ) was a significant risk factor for subsequent tumour recurrence ( P = 0.002; hazard ratio [HR] 2.15). Additional BCG instillation significantly decreased the subsequent tumour recurrence rate ( P < 0.001; HR 0.41). Multivariate analysis also showed that a relapsing tumour with a pathologically high risk was also significantly associated with stage progression ( P < 0.001; HR 8.05). CONCLUSIONS: An additional course of BCG instillation might be effective in patients with BCG‐relapsing tumours with pathologically intermediate risk. Nevertheless, some patients with high‐risk pathological features developed subsequent stage progression. Such patients should be followed up closely and counselled on the need for aggressive therapeutic options, such as radical cystectomy.
10 April 2020 in Surgical Case Reports
Background: Intramural metastasis is rare in colorectal cancer, especially metastasis of ascending colon cancer to the appendix. Case presentation: A 64-year-old man was admitted to our hospital for surgery for ascending colon cancer detected by medical examination. Colonoscopy identified a type-2 tumor in the ascending colon, which was diagnosed as adenocarcinoma. Abdominal computed tomography revealed focal thickening of the ascending colon and middle of the appendix and swelling of the lymph nodes around the ileocolic artery. The patient underwent laparoscopic right hemi-colectomy with D3 lymph node dissection. Histopathological findings revealed that the ascending colon cancer was moderately differentiated adenocarcinoma with lymphatic and vascular invasion (stage IIIB; pT3N2M0). Additionally, moderately differentiated adenocarcinoma was observed mainly in the submucosa and muscularis propria of the appendix, which was approximately 10 cm proximal to the ascending colon cancer. These findings indicated intramural metastasis to the appendix from the ascending colon cancer. The patient experienced recurrence with lung metastasis 2.5 years after the first surgery. Conclusions: Intramural metastasis of ascending colon cancer to the appendix is extremely rare. Because the risk of recurrence and the prognosis for intramural metastasis has not been clarified, careful follow-up is recommended.